- Home
- BCRX vs RLX Comparison
BCRX vs RLX Comparison
Compare BCRX & RLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCRX | RLX |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BCRX | RLX |
|---|---|---|
| Price | $9.95 | $1.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 1 |
| Target Price | ★ $20.82 | $2.50 |
| AVG Volume (30 Days) | 2.9M | ★ 3.2M |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | ★ 0.75% |
| EPS Growth | ★ 381.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,186,000.00 | N/A |
| Revenue This Year | N/A | $55.89 |
| Revenue Next Year | $12.55 | $15.07 |
| P/E Ratio | ★ N/A | $28.09 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.00 | $1.74 |
| 52 Week High | $11.22 | $2.68 |
Technical Indicators
Market Signals| Indicator | BCRX | RLX |
|---|---|---|
| Relative Strength Index (RSI) | 55.95 | 37.00 |
| Support Level | $8.79 | $1.76 |
| Resistance Level | $10.32 | $2.08 |
| Average True Range (ATR) | 0.32 | 0.06 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 81.17 | 22.22 |
Price Performance
Historical ComparisonAbout BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market. The company has two reportable segments, Core Markets and Europe Acquisition. The majority of the revenue is earn from Core Markets segment.